In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Three investors take part in Vical's $19mm RDO

Executive Summary

In a registered direct offering, Federated Kaufmann Fund, Special Situations Funds, and an undisclosed backer have purchased 8.7mm shares of Vical (DNA vaccines for cancer and infections, and therapeutic growth factors for peripheral and coronary artery diseases) common stock for $2.31 apiece (a 3% premium), netting the company $19mm. The investors also received a 90-day option to buy 4.3mm shares for $2.25 each. Rodman & Renshaw was the placement agent.
Deal Industry
  • Pharmaceuticals
  • Pharmaceuticals
    • Vaccines
    • Drug Delivery
      • Macromolecule
  • Biotechnology
    • Gene Therapy, Cell Therapy
    • Large Molecule
Deal Status
  • Final
Deal Type
  • Financing
    • Private Investment in Public Equity
    • Private Placement

Related Companies